Page 2 - Indian Pharmaceuticals Industry

Covid-19 lockdown: After April shock, drug sales improve in May

Till May 15, the overall inventory was 39 days, compared to 43 days in first half of the previous month

Centre looks to nudge more MSMEs into manufacturing to reduce imports

Sources across ministries confirmed that Narendra Modi's call to "go vocal for local" will be achieved through a host of measures, running into the dozens, and will focus on long-term goals.

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Antibiotic sales drive domestic pharma mkt down 11.2% in lockdown-hit April

Sale of anti-infectives (11% of domestic pharma market) fell by 21.5%, while gynaecological and dermatological drugs fell by about 23%

Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir

The drug, which is an injectable, got emergency approval from the US drug regulator recently.

Lockdown 3.0: Pharma hubs take extra precaution to tame Covid-19 outbreak

Recently, while 26 workers at Cadila Pharmaceuticals facility in Ahmedabad tested positive for Covid-19, one person at Sun Pharma's Halol plant tested positive.

Serum Institute hopes to roll out a Covid-19 vaccine. Is this realistic?

The Pune-based company plans to start trials on people to assess whether the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis can also protect against the Covid-19 virus.

India to send nearly 1K tonnes of paracetamol raw material to Europe

The Indian government in March put a hold on exports of several drugs including paracetamol to secure supplies for its people after the Covid-19 outbreak disrupted the industry's supply chain globally

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

This pharma hub gets back on its feet after relief in locked-down India

Baddi accounts for 35-40 per cent of India's domestic pharmaceutical output

Lockdown hits production of anti-TB drugs, health min seeks to ban export

In a letter to various departments, the health ministry has said the "situation calls for extraordinary measures" to make sure that TB patients do not face challenges in diagnosis or treatment.

Coronavirus outbreak: India plans ayurvedic trials on patients soon

On the preventive front, many states, including Haryana, Goa and Kerala, have started using ayurvedic medicines for asymptomatic patients and even frontline workers.

Coronavirus impact: Enough stock of hydroxychloroquine in India, says govt

Joint Secretary in the Ministry of Health Lav Agarwal said that India has a stock of 3.28 crore tablets of hydroxychloroquine, which is three times more than the projected requirement

Covid-19 impact: Hydroxychloroquine's share in pharma exports minuscule

Manufacturers say there is enough stock for local needs

Coronavirus outbreak: Pharma market grows 9% in March due to panic buying

Cardio-diabetic and respiratory segments clock robust growth

Coronavirus impact: Ipca, Cadila Healthcare stocks gain on India's HCQ move

Apart from the US, Brazil and Sweden have requested for the drug to battle the Covid-19 scare in their countries.

India lifts curbs on exports of 13 active pharmaceutical ingredients

In the first week of March, India restricted the exports of 13 APIs and their formulations to ensure there was no shortage in the domestic market.

Clinical trial norms may be eased for developing coronavirus vaccine

Sources said no fresh approvals would be given for clinical trials, except for those related to Covid-19.

Covid-19: Working with govt to ensure smooth supply of medicines, says IPA

The pharma industry body also said that it is not aware of any medicines shortage, to date

Indian Pharmaceutical Alliance says it is committed to help fight Covid-19

Towards this, the alliance and its members are working with the governments and other public agencies, pharma industry associations and all other key stakeholders, it said in a statement